CA
AURA icon

CoreCap Advisors’s Aura Biosciences AURA Stock Holding History

CoreCap Advisors’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33
Closed -$193 – 2797
2025
Q1 		$193 Buy
+33
New +$250 ﹤0.01% 2989

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

CoreCap Advisors's AURA Position: Q2 2025 in Review

CoreCap Advisors sold out of Aura Biosciences (AURA) in Q2 2025, closing a stake of 33 shares — an estimated $193 sold.

CoreCap Advisors first reported a position in AURA in Q1 2025 and held it in 1 quarter. The position peaked at $193 in Q1 2025. 104 funds tracked by Wall St. Rank hold AURA as of Q2 2025.

  • CoreCap Advisors reported no remaining Aura Biosciences position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 33 Aura Biosciences shares in Q2 2025, an estimated $193.
  • CoreCap Advisors first reported a position in Aura Biosciences in Q1 2025 and held it in 1 quarter.
  • CoreCap Advisors's Aura Biosciences position peaked at $193 in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.